doubleblind
placebo
control
trial
intranas
npc
bradykinin
antagonist
fail
allevi
symptom
experiment
rhinoviru
cold
inde
evid
drug
enhanc
symptom
although
irrit
effect
detect
uninfect
nasal
mucosa
rhinoviru
bradykinin
antagonist
npc
human
volunt
correspond
pg
higgin
mrc
common
cold
unit
harvard
hospit
salisburi
wiltshir
uk
attempt
demonstr
presenc
certain
mediat
tissu
reaction
infect
eg
histamin
leukotrien
nasal
secret
individu
cold
prove
neg
best
equivoc
eggleston
et
al
naclerio
et
al
callow
et
al
proud
et
al
howev
kinin
includ
bradykinin
shown
gener
coryz
phase
experiment
naclerio
et
al
natur
proud
et
al
rhinoviru
infect
intranas
administr
bradykinin
produc
symptom
indistinguish
rhinoviru
cold
proud
et
al
npc
bradykinin
antagonist
darg
hyp
dphe
inhibit
respons
bradykinin
vitro
competit
blockad
kinin
receptor
condit
npc
bind
activ
bradykinin
burch
et
al
efficaci
intranas
npc
rhinoviru
induc
cold
human
subject
therefor
investig
studi
treatment
began
cold
initi
elsewher
studi
treatment
began
cold
symptom
appear
time
would
suitabl
applic
clinic
practic
trial
approv
harrow
district
ethic
committe
northwick
park
conduct
accord
standard
procedur
doubleblind
placebocontrol
trial
bear
reed
permit
daili
assess
cold
mean
clinic
score
nasal
secret
weight
addit
overal
evalu
cold
brief
quarantin
period
healthi
volunt
challeng
rhinoviru
type
h
later
rhinoviru
strain
el
develop
cold
h
challeng
selfadminist
placebo
npc
mgml
ml
nostril
six
time
day
end
trial
maximum
five
day
member
staff
supervis
administr
spray
contain
sodium
chlorid
wv
citric
acid
sodium
citrat
distil
water
preserv
methyl
paraben
propyl
paraben
placebo
consist
vehicl
without
drug
randomis
partial
trial
includ
femal
order
ensur
risk
pregnanc
would
receiv
placebo
volunt
remain
isol
throughout
assess
clinic
everi
day
nasal
wash
viru
isol
collect
daili
commenc
h
viru
challeng
blood
sampl
haematolog
biochem
test
wele
collect
volunt
entri
trial
receiv
medic
end
trial
order
evalu
transient
relief
symptom
might
result
medic
volunt
ask
assess
sever
cold
well
four
symptom
block
nose
runni
nose
sore
throat
cough
analogu
cm
scale
graduat
assess
made
immedi
one
hour
dose
medic
day
second
assess
made
ident
scale
adjac
first
fortyf
subject
took
part
one
two
doubleblind
placebocontrol
toler
studi
conduct
nova
pharmaceut
corpor
unpublish
data
medic
consist
dose
ml
npc
mgml
placebo
intranas
six
day
well
toler
volunt
took
part
similar
toler
studi
dose
medic
ccu
one
volunt
placebo
withdrawn
studi
epistaxi
total
clinic
score
remain
subject
nil
unpublish
data
cours
six
trial
volunt
allot
efficaci
studi
femal
includ
last
two
trial
regulatori
permiss
receiv
number
six
subject
exclud
two
wild
cold
two
contact
wild
cold
one
abnorm
biochem
test
result
one
withdrew
domest
reason
remain
volunt
diagnos
suffer
cold
requisit
time
given
medic
l
receiv
npc
placebo
two
group
well
balanc
sex
age
see
tabl
three
cold
drug
group
class
moder
remain
eight
mild
compar
cold
placebo
group
grade
mild
mean
total
clinic
score
mean
total
nasal
secret
weight
drug
group
g
respect
compar
g
placebo
group
differ
reach
statist
signific
level
evid
effect
men
infertil
femal
analys
separ
data
shown
accur
apprais
effect
npc
cours
rhinoviru
cold
obtain
compar
mean
daili
clinic
score
mean
daili
nasal
secret
weight
two
group
onset
cold
see
figur
mean
daili
clinic
score
mean
daili
nasal
secret
weight
similar
two
group
first
day
thereaft
valu
drug
group
alway
greater
placebo
group
mark
mean
daili
nasal
secret
weight
differ
reach
statist
signific
nasal
secret
day
p
two
paramet
entir
independ
number
tissu
use
reflect
amount
nasal
secret
contribut
significantli
clinic
score
mean
daili
clinic
score
recalcul
exclud
valu
attribut
tissu
count
ie
evalu
cold
symptom
runni
nose
pattern
two
group
becom
much
closer
inde
revers
day
see
figur
volunt
analogu
assess
cold
chang
mm
less
ignor
chang
sever
cold
symptom
record
assess
made
npc
recipi
compar
assess
made
given
placebo
drug
group
improv
record
instanc
increas
sever
correspond
figur
placebo
group
respect
chang
excess
mm
indic
substanti
chang
sever
occur
assess
npc
group
symptom
consid
increas
sever
chang
common
placebo
group
instanc
among
assess
one
signifi
benefici
effect
littl
evid
npc
produc
consist
short
term
effect
volunt
often
improv
one
day
counterbalanc
deterior
anoth
placebo
consist
effect
gener
benefici
howev
interest
note
substanti
chang
occur
among
placebo
recipi
report
two
subject
probabl
relat
person
volunt
medic
similarli
data
fail
support
hypothesi
import
stage
cold
medic
given
variat
haematolog
biochem
valu
obtain
medic
similar
drug
placebo
recipi
medic
commenc
two
group
well
match
sever
cold
similar
possibl
make
formal
power
calcul
day
onset
cold
fig
result
daili
assess
volunt
given
bradykinin
antagonist
npc
placebo
first
day
rhinoviru
common
cold
studi
earlier
prophylact
studi
similar
size
estim
reduct
symptom
could
detect
trial
p
must
realis
clinic
score
allot
subject
day
reflect
clinic
condit
time
symptom
experienc
tissu
use
previou
hour
therefor
major
clinic
score
nasal
secret
weight
day
acquir
medic
commenc
medic
start
cold
receiv
drug
sever
placebo
group
although
differ
statist
signific
one
occas
mean
nasal
secret
weight
day
greater
sever
cold
drug
group
attribut
increas
nasal
secret
seen
contribut
tissu
count
deduct
clinic
score
see
fig
furthermor
volunt
assess
show
evid
specif
short
term
benefici
effect
npc
although
placebo
effect
approxim
selfassess
chang
consid
benefici
group
howev
substanti
chang
three
four
drug
group
advers
compar
similar
chang
placebo
group
benefici
evid
npc
benefici
effect
cours
rhinoviru
induc
cold
inde
clinic
observ
volunt
selfassess
would
appear
drug
act
mild
irrit
despit
evid
obtain
toler
studi
irrit
effect
must
attribut
drug
placebo
contain
ingredi
vehicl
howev
observ
previous
antivir
innocu
normal
nasal
epithelium
irrit
alreadi
inflam
mucosa
et
al
sever
possibl
reason
failur
demonstr
benefici
effect
npc
man
dosag
may
insuffici
drug
may
fail
reach
kinin
receptor
npc
inhibit
bind
bradykinin
neuroblastoma
cell
bind
constant
ki
nm
guinea
pig
ileum
membran
ki
nm
concentr
shown
inhibit
bradykininmedi
effect
anim
model
unpublish
npc
bind
capac
bradykinin
receptor
would
alreadi
expos
cold
becom
clinic
appar
place
drug
distinct
competit
disadvantag
might
inhibit
compon
nasal
secret
biolog
inhibitor
known
moment
lastli
possibl
bradykinin
play
domin
role
coryza
rhinoviru
induc
cold
